CN Patent

CN105579444B — 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途

Assigned to Novartis AG · Expires 2018-05-01 · 8y expired

What this patent protects

本发明提供了式I的化合物：用于制备本发明的化合物的方法、以及其作为补体旁路途径的抑制剂、特别是因子B的抑制剂的治疗用途。本发明还提供了药物活性剂的组合产品和药物组合物。

USPTO Abstract

本发明提供了式I的化合物：用于制备本发明的化合物的方法、以及其作为补体旁路途径的抑制剂、特别是因子B的抑制剂的治疗用途。本发明还提供了药物活性剂的组合产品和药物组合物。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN105579444B
Jurisdiction: CN
Classification: —
Expires: 2018-05-01
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.